ONeil Trader
Latest Articles
LGI Homes: Growth To Slow Down In 2018
Amicus Therapeutics: What To Expect In 2018
Neos Therapeutics: Cotempla Off To A Strong Start
Omeros: OMS721 Updates Are Very Positive, But Where's The Update On Omidria?
Biotech: The Tide Is Turning
Global Blood Therapeutics: The Significance Of ASH Updates
Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold
The Investment Case For Ascendis Pharma
Selecta Biosciences: SEL-212 Phase 2 Data Not As Good As Hoped, But The Potential Is Still There
RedHill Biopharma: When Good News Means Nothing
Flexion Therapeutics: Zilretta Approved, Now What?
Omeros: One Overhang Removed, One Remaining
A Lost Year For OPKO Health
Supernus: Market Overreacts After Interim Analysis Of SPN-810 Phase 3 Trial
BioDelivery Sciences: Change Is Good?
LGI Homes: Still Well Positioned To Grow
Baozun: More Room To Run?
Neos Therapeutics: Focusing On Execution
Lexicon Pharmaceuticals: Stock Out Of Favor But Fundamentals Improving
Omeros: A Breakout Quarter For Omidria
Neurocrine Biosciences: Ingrezza's Strong Launch, Pipeline To Create Value
The Investment Case For Global Blood Therapeutics
Sucampo: A Shift Toward Rare Diseases
58.Com: A Secular Growth Story
Acorda's Pipeline Has Potential
Omeros' Pipeline Starting To Get The Recognition It Deserves
The Investment Case For Flexion Therapeutics
Vanda: Several Catalysts Coming Up
New Data Validate Amicus's Pompe Disease Candidate
Neos Therapeutics: Important Catalyst Coming Up
Revisiting The Investment Case On Supernus
BioDelivery Sciences: Belbuca's Progress Is Encouraging